Riyaz Shah: HER2-Directed Therapies for Advanced HER2-Mutant NSCLC
Riyaz Shah/circlehealthgroup.co.uk

Riyaz Shah: HER2-Directed Therapies for Advanced HER2-Mutant NSCLC

Riyaz Shah, Consultant Medical Oncologist at Cromwell Hospital, shared on LinkedIn:

“Lovely analysis in HER2 mutated NSCLC demonstrating that in the absence of H2H data, on balance the TKI’s have it. ADC activity maintained post TKI.

TKI good in YVMA + active in non-TKD mutations. This is a very exciting space with lots happening.”

Title: Efficacy and Safety of HER2-Directed Therapies for Advanced HER2-Mutant NSCLC: A Systematic Review and Meta-Analysis.

Authors: Molly Li, Yu Yang Soon, Pui Yin Au-Yeung, Andrew Chan, Jii-Bum Lee, Jorn Nutzinger, Akiko Tateishi, Ross Soo.

Full article.

You can also read: Oncogene-Driven NSCLC in 2026: Targeted Therapy Expands Across Mutations, Resistance and CNS Disease.

Riyaz Shah